Cotiviti Announces Potential Pricing for IPO

Cotiviti Holdings filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 12.5 million shares in the range of $17 to $19 per share, with an overallotment option for 1.875 million shares. At the maximum price, the entire offering is valued up to $273.125 million. The company intends to list its shares on the New York Stock Exchange under the symbol COTV.

The underwriters for the offering are Goldman Sachs, JPMorgan, Barclays, Citigroup, Credit Suisse, Morgan Stanley, RBC Capital Markets, SunTrust Robinson Humphrey, Baird and William Blair.

This is a leading provider of analytics-driven payment accuracy solutions, focused primarily on the health care sector. Its integrated solutions help clients enhance payment accuracy in an increasingly complex health care environment. Cotiviti leverages its robust technology platform, configurable analytics, proprietary information assets and expertise in health care reimbursement to help clients enhance their claims payment accuracy.

[nativounit]

Cotiviti helps its health care clients identify and correct payment inaccuracies, which resulted in over $2.7 billion in savings in 2015. The company works with over 40 health care organizations, including eight of the 10 largest U.S. commercial, Medicare and Medicaid managed health plans, as well as the Centers for Medicare & Medicaid Services. This is also a leading provider of payment accuracy solutions to over 40 retail clients, including eight of the 10 largest retailers in the United States.

In the filing, Cotiviti detailed its finances as:

Our track record of consistently delivering value for our clients has enabled strong growth in our revenue and profitability, especially within our core healthcare payer client base. For the three months ended March 31, 2016 and the year ended December 31, 2015, our total revenue was $142.7 million and $541.3 million, respectively. In this same period, we generated Adjusted EBITDA of $50.6 million and $203.4 million, respectively, representing 35.5% and 37.6% of revenue, respectively, and net income of $8.1 million and $13.9 million, representing 5.7% and 2.6% of revenue.

The company intends to use the net proceeds of the offering to repay its indebtedness and for general corporate purposes.